CN113727995A - 检测癌的方法和检测试剂 - Google Patents

检测癌的方法和检测试剂 Download PDF

Info

Publication number
CN113727995A
CN113727995A CN202080030591.0A CN202080030591A CN113727995A CN 113727995 A CN113727995 A CN 113727995A CN 202080030591 A CN202080030591 A CN 202080030591A CN 113727995 A CN113727995 A CN 113727995A
Authority
CN
China
Prior art keywords
antibody
azu1
cancer
reagent
azu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030591.0A
Other languages
English (en)
Chinese (zh)
Inventor
植田幸嗣
大西直美
辻川和丈
野野村祝夫
植村元秀
神宫司健太郎
大竹则久
河合康俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
Tosoh Corp
University of Osaka NUC
Original Assignee
Japanese Foundation for Cancer Research
Osaka University NUC
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research, Osaka University NUC, Tosoh Corp filed Critical Japanese Foundation for Cancer Research
Publication of CN113727995A publication Critical patent/CN113727995A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format
    • G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
CN202080030591.0A 2019-04-24 2020-04-15 检测癌的方法和检测试剂 Pending CN113727995A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019082912 2019-04-24
JP2019-082912 2019-04-24
PCT/JP2020/016607 WO2020218121A1 (ja) 2019-04-24 2020-04-15 癌を検出する方法および検出試薬

Publications (1)

Publication Number Publication Date
CN113727995A true CN113727995A (zh) 2021-11-30

Family

ID=72942515

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030591.0A Pending CN113727995A (zh) 2019-04-24 2020-04-15 检测癌的方法和检测试剂

Country Status (5)

Country Link
US (1) US20220178932A1 (https=)
EP (1) EP3960758A4 (https=)
JP (1) JP7546255B2 (https=)
CN (1) CN113727995A (https=)
WO (1) WO2020218121A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7661767B2 (ja) * 2021-04-28 2025-04-15 東ソー株式会社 細胞外小胞の検出方法
JPWO2024203968A1 (https=) * 2023-03-24 2024-10-03
WO2025197993A1 (ja) * 2024-03-22 2025-09-25 学校法人東邦大学 テトラスパニン１０陽性細胞外小胞の濃縮方法、及びがんを検出する又はがんの予後を予測する方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162368A1 (en) * 2012-04-26 2013-10-31 Stichting Vu-Vumc Biomarkers
EP2803673A1 (en) * 2011-12-26 2014-11-19 Shionogi & Co., Ltd. Monoclonal antibody for detecting exosomes
WO2015083791A1 (ja) * 2013-12-04 2015-06-11 国立研究開発法人理化学研究所 肺癌の検出方法および検出キット
US20170153240A1 (en) * 2015-11-30 2017-06-01 Sungkwang Medical Foundation Composition, kit, and method for diagnosing and treating ovarian cancer
WO2018217087A1 (en) * 2017-05-23 2018-11-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel stool-based protein biomarkers for colorectal cancer screening

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502522A (en) 1976-11-25 1978-03-01 Gestetner Ltd Stencil ejector on a stencil duplicator
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
JP5488885B2 (ja) 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
KR102582192B1 (ko) 2014-12-05 2023-09-25 후지필름 가부시키가이샤 Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트
EP3543701A4 (en) 2016-10-28 2020-07-29 Japanese Foundation For Cancer Research BIOMARKER, METHOD OF SEARCHING FOR A GENE ASSOCIATED WITH A DISEASE, AND MARKER FOR KIDNEY CANCER
CN115047182B (zh) * 2017-10-05 2025-03-11 香港科技大学 外泌体分析及癌症诊断方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2803673A1 (en) * 2011-12-26 2014-11-19 Shionogi & Co., Ltd. Monoclonal antibody for detecting exosomes
US20150010913A1 (en) * 2011-12-26 2015-01-08 Shionogi & Co., Ltd. Monoclonal antibody for detecting exosomes
WO2013162368A1 (en) * 2012-04-26 2013-10-31 Stichting Vu-Vumc Biomarkers
WO2015083791A1 (ja) * 2013-12-04 2015-06-11 国立研究開発法人理化学研究所 肺癌の検出方法および検出キット
US20170153240A1 (en) * 2015-11-30 2017-06-01 Sungkwang Medical Foundation Composition, kit, and method for diagnosing and treating ovarian cancer
WO2018217087A1 (en) * 2017-05-23 2018-11-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel stool-based protein biomarkers for colorectal cancer screening

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAN X. ET AL.: "A quantitative proteomics study on olfactomedin 4 in the development of gastric cancer", INT. J. ONCOL, vol. 47, no. 5, pages 1932 - 1944, XP093009833, DOI: 10.3892/ijo.2015.3168 *
RAN, XIAOPING ET AL.: "A quantitative proteomics study on olfactomedin4 in the development of gastric cancer", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 47, no. 5, 16 September 2015 (2015-09-16), pages 1942 *
赵雪, 吴霖, 顾勤: "β-内酰胺酶在胃癌中的表达及临床意义", 上海交通大学学报(医学版), vol. 38, no. 10, 10 October 2018 (2018-10-10), pages 1212 *

Also Published As

Publication number Publication date
EP3960758A4 (en) 2023-02-15
JP7546255B2 (ja) 2024-09-06
JPWO2020218121A1 (https=) 2020-10-29
EP3960758A1 (en) 2022-03-02
WO2020218121A1 (ja) 2020-10-29
US20220178932A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
AU2015254257B2 (en) Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
US9347954B2 (en) Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same
CN107001437B (zh) 卵巢透明细胞腺癌的检查方法及检查药
US20120271124A1 (en) Thrombospondin Fragments and Uses Thereof In Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents
CN108473552B (zh) 检测外泌体蛋白eif3a的特异性自身抗体的抗原性组合物和使用其诊断肝癌的方法
KR20120123248A (ko) 악성 종양의 진단 방법
JP7546255B2 (ja) 癌を検出する方法および検出試薬
JP7127422B2 (ja) 癌を検出する方法及び検出試薬
CN107973855A (zh) 与糖肽反应的单克隆抗体及其用途
RU2607588C2 (ru) Способ получения агента, связывающегося с препро-вазопрессином или с его фрагментами
JP6829444B2 (ja) 去勢抵抗性前立腺癌を検出する方法及び検出試薬
CN111656196A (zh) 肾癌的检测方法和检查试剂
CN103842503A (zh) 上皮性卵巢癌标志物检测用抗体和上皮性卵巢癌判定方法
CN107857815B (zh) 与糖肽反应的单克隆抗体及其用途
CN111303289B (zh) 抗人Tn型糖基化MUC1抗体及其用途
JP7306661B2 (ja) 消化管間質腫瘍を検出する方法および検出試薬
JP6760562B2 (ja) 卵巣明細胞癌患者の予後を予測するための情報提供方法
WO2021246153A1 (ja) 膵臓がんの検出方法及び検出試薬
US9127054B2 (en) Immunoassay of cofilin 1 protein
EP4317172A1 (en) Immunological analysis method for type-i collagen c-terminal telopeptide
EP4063845A1 (en) Method for detecting cancer bone metastasis and detection reagent
CN102597772B (zh) 5.9kDa肽的免疫学测定方法
CN103842504A (zh) 上皮性卵巢癌标志物检测用抗体和上皮性卵巢癌判定方法
CN115151821A (zh) 卵巢恶性肿瘤的检测方法和检测试剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination